₹ 1,698.60 -21.10 (-1.23%)
- NSE
- BSE
Overview
- BSE Code 535022
- NSE Symbol BETA
- ISIN Demat INE351Y01019
- Book Value (₹)
- Face Value (₹) 10.00
- Market Cap (₹ Cr.)
- P/E (TTM)
- EPS (TTM)
- Div Yield (%)
Performance
Corporate Actions
Beta Drugs Limited - Disclosure under SEBI Takeover Regulations
Apr 08, 2025Beta Drugs Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
Beta Drugs Limited - Certificate under SEBI (Depositories and Participants) Regulations, 2018
Apr 08, 2025Beta Drugs Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
About Beta Drugs Ltd
Beta Drugs Limited was established as a private limited company with the name 'Beta Drugs Private limited' at Himachal Pradesh on September 21, 2005. Subsequently, the Company was converted in to public limited company and the name of the Company was changed to 'Beta Drugs Limited' on August 11, 2017
Beta Drugs is a part of Adley Group. Adley Group was founded in the year 1985, by its promoter Vijay Batra, who has more than twenty five years of experience in manufacture of pharmaceutical products in India. the Company is a pharmaceutical formulation manufacturing company engaged in developing, manufacturing and marketing of drug products for domestic and international customers. The Promoter Vijay Batra, took over the Company from Kiran Goyal, Deepak Kumar Prince Bharti and Rohit Bansal in the year 2014.
the Company is primarily engaged in the manufacturing of oncology products. the Company's products range from anti-cancer tablets, capsules, injections and lyophilized injections. the Company started production of oncology products by manufacturing portfolio of over 35 products which is used for the treatment of various cancer disease.
the Company set up the first Oncology Unit in Adley Formulations Pvt Ltd. in 2008. It set up a new 'state of the art' manufacturing facility for oncology formulations in 2014; developed in-house Albumin bound Paclitaxel in 2015; started in-house API Plant - Adley Labs in 2017.
In October, 2017, the Company came up with a Public Issue of 22,96,000 Equity Shares by raising equity capital aggregating Rs 19.5 Crores.
the Company set up an Oncology Plant in Uzbekistan in 2018. In 2020, the Company launched GEM-RTU, ADLEAP, ADLANTE, BEXINIB; launched 1st Indian Brand of Dasatinib, BEEDAN. In 2021, the Company launched 1st Indian brand of Sunitinib, ADSUNIB.
Founded | : 2005 |
Chairman | : Rahul Batra |
Managing Director | : Rahul Batra |
Address | : Village Nandpur, Baddi, Himachal Pradesh, 174101, |
- PAN Card
- Cancelled Cheque
- Latest 6 month Bank Statement (Only for Derivatives Trading)